Current Urology Reports

, 18:77 | Cite as

Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation

  • Marcelino Rivera
  • Amy Krambeck
  • James Lingeman
Benign Prostatic Hyperplasia (K McVary, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Benign Prostatic Hyperplasia


Purpose of Review

This is to evaluate and discuss the literature surrounding holmium laser enucleation of the prostate (HoLEP) in patients on anticoagulation.

Recent Findings

The relationship of benign prostatic hyperplasia (BPH) to bothersome lower urinary tract symptoms (LUTS) is well established with a majority of men over the age of 60 having significant symptoms. Patients with severe enough symptoms often require surgery and with cardiovascular disease ranking as the primary cause of death in the USA, a growing number will be taking antiplatelet (AP) or anticoagulation (AC) for primary or secondary prevention of disease. A review of the recent literature focusing on patients on AP/AC undergoing HoLEP noted minimal adverse effects in the postoperative course aside from prolonged bleeding requiring catheterization with continuous bladder irrigation.


Although patients with BPH and bothersome LUTS undergoing HoLEP are at a slightly greater risk for prolonged bladder irrigation secondary to bleeding, surgical outcomes are similar to men not on AP/AC. The literature surrounding newer direct oral anticoagulants (DOACs) and HoLEP is limited, and therefore, conclusions regarding continuation of DOACs cannot be drawn. However, HoLEP appears to be a safe and effective procedure for BPH-related LUTS in patients on AP/AC therapy.


Lower urinary tract symptoms Benign prostatic obstruction Holmium laser enucleation of the prostate (HoLEP) Anticoagulation 



Lower urinary tract symptoms


Benign prostatic hyperplasia


Holmium laser enucleation of the prostate


Venous thromboembolism


Dual antiplatelet therapy






Acute urinary retention


direct oral anticoagulants


Coronary artery bypass grafting


American Society of Anesthesiologists


Compliance with Ethical Standards

Conflict of Interest

Marcelino Rivera declares no potential conflicts of interest.

Amy Krambeck reports personal fees from Lumenis, Boston Scientific, and Thermedx.

James Lingeman reports personal fees from Lumenis, Boston Scientific, and Beck Analytical; is an owner and medical directory of Beck Analytical; and owner and investor of Midwest Mobile Lithotripsy.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology. 2002;59(6):877–83.CrossRefPubMedGoogle Scholar
  2. 2.
    Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175(1):217–220; discussion 20-1. doi: 10.1016/S0022-5347(05)00041-8.CrossRefPubMedGoogle Scholar
  3. 3.
    Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. doi: 10.1016/j.eururo.2009.09.035.CrossRefPubMedGoogle Scholar
  4. 4.
    Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med. 2011;171(10):914–20. doi: 10.1001/archinternmed.2011.170.CrossRefPubMedGoogle Scholar
  5. 5.
    Groves HK, Chang D, Palazzi K, et al. The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis. 2013;16(3):260–5. doi: 10.1038/pcan.2013.11.CrossRefPubMedGoogle Scholar
  6. 6.
    Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N.CrossRefPubMedGoogle Scholar
  7. 7.
    Becker B, Knipper S, Gross AJ, et al. Current management in transurethral therapy of benign prostatic obstruction in patients on oral anticoagulation: a worldwide questionnaire. J Endourol. 2017;31(2):163–8. doi: 10.1089/end.2016.0627.CrossRefPubMedGoogle Scholar
  8. 8.
    Tan AH, Gilling PJ, Kennett KM, et al. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170(4 Pt 1):1270–4. doi: 10.1097/01.ju.0000086948.55973.00.CrossRefPubMedGoogle Scholar
  9. 9.
    • El Tayeb MM, Jacob JM, Bhojani N, et al. Holmium laser enucleation of the prostate in patients requiring anticoagulation. J Endourol. 2016;30(7):805–9. doi: 10.1089/end.2016.0070. The largest series of HoLEP patients on AC/AP therapy noted slightly longer continuous bladder irrigation but no longterm adverse sequalae. CrossRefPubMedGoogle Scholar
  10. 10.
    Tyson MD, Lerner LB. Safety of holmium laser enucleation of the prostate in anticoagulated patients. J Endourol. 2009;23(8):1343–6. doi: 10.1089/end.2009.0013.CrossRefPubMedGoogle Scholar
  11. 11.
    • Bishop CV, Liddell H, Ischia J, et al. Holmium laser enucleation of the prostate: comparison of immediate postoperative outcomes in patients with and without antithrombotic therapy. Curr Urol. 2013;7(1):28–33. doi: 10.1159/000343549. In a recent retrospective review the authors noted resection rates, operative times and enucleated weights were not different between the two cohorts. A transfusion rate of 7.7% was noted in the AC/AP group. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54(14):1280–9. doi: 10.1016/j.jacc.2009.04.091.CrossRefPubMedGoogle Scholar
  13. 13.
    Chai-Adisaksopha C, Crowther M, Isayama T, et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8. doi: 10.1182/blood-2014-07-590323.CrossRefPubMedGoogle Scholar
  14. 14.
    Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2013;61(6):651–8. doi: 10.1016/j.jacc.2012.09.057.CrossRefPubMedGoogle Scholar
  15. 15.
    Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97. doi: 10.1056/NEJMoa1113572.CrossRefGoogle Scholar
  16. 16.
    Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev. 2017;31(1):77–84. doi: 10.1016/j.blre.2016.08.006.CrossRefPubMedGoogle Scholar
  17. 17.
    Rogers KC, Shelton MP, Finks SW. Reversal agents for direct oral anticoagulants: understanding new and upcoming options. Cardiol Rev. 2016;24(6):310–5. doi: 10.1097/CRD.0000000000000118.CrossRefPubMedGoogle Scholar
  18. 18.
    Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–55. doi: 10.1161/CIR.0000000000000404.CrossRefPubMedGoogle Scholar
  19. 19.
    Humphreys MR, Miller NL, Handa SE, et al. Holmium laser enucleation of the prostate—outcomes independent of prostate size? J Urol. 2008;180(6):2431–2435; discussion 35. doi: 10.1016/j.juro.2008.08.019.CrossRefPubMedGoogle Scholar
  20. 20.
    Krambeck AE, Handa SE, Lingeman JE. Holmium laser enucleation of the prostate for prostates larger than 175 grams. J Endourol. 2010;24(3):433–7. doi: 10.1089/end.2009.0147.CrossRefPubMedGoogle Scholar
  21. 21.
    Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008;53(1):160–6. doi: 10.1016/j.eururo.2007.08.036.CrossRefPubMedGoogle Scholar
  22. 22.
    Gilling PJ, Wilson LC, King CJ, et al. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int. 2012;109(3):408–11. doi: 10.1111/j.1464-410X.2011.10359.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Descazeaud A, Robert G, Lebdai S, et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol. 2011;29(2):211–6. doi: 10.1007/s00345-010-0561-3.CrossRefPubMedGoogle Scholar
  24. 24.
    Taylor K, Filgate R, Guo DY, et al. A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int. 2011;108(Suppl 2):45–50. doi: 10.1111/j.1464-410X.2011.10686.x.CrossRefPubMedGoogle Scholar
  25. 25.
    Gravas S, Bachmann A, Reich O, et al. Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int. 2011;107(7):1030–43. doi: 10.1111/j.1464-410X.2010.09954.x.CrossRefPubMedGoogle Scholar
  26. 26.
    Gilling PJ, Cass CB, Cresswell MD, et al. Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Urology. 1996;47(1):48–51.CrossRefPubMedGoogle Scholar
  27. 27.
    Health Quality O. Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(17):1–121.Google Scholar
  28. 28.
    Hochreiter WW, Thalmann GN, Burkhard FC, et al. Holmium laser enucleation of the prostate combined with electrocautery resection: the mushroom technique. J Urol. 2002;168(4 Pt 1):1470–4. doi: 10.1097/01.ju.0000025336.31206.25.PubMedGoogle Scholar
  29. 29.
    Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol. 2006;175(4):1428–32. doi: 10.1016/S0022-5347(05)00645-2.CrossRefPubMedGoogle Scholar
  30. 30.
    Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250–5. doi: 10.1124/dmd.112.046888.CrossRefPubMedGoogle Scholar
  31. 31.
    Dash D. Current status of antiplatelet therapy in acute coronary syndrome. Cardiovasc Hematol Agents Med Chem. 2015;13(1):40–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Poulakos M, Walker JN, Baig U, et al. Edoxaban: a direct oral anticoagulant. Am J Health Syst Pharm. 2017;74(3):117–29. doi: 10.2146/ajhp150821.CrossRefPubMedGoogle Scholar
  33. 33.
    Guirguis E, Brown D, Grace Y, et al. Establishing Edoxaban’s role in anticoagulation. J Pharm Pract. 2016;29(3):228–38. doi: 10.1177/0897190016647314.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang YJ, Li MP, Tang J, et al. Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int J Environ Res Public Health 2017; 14(3) doi:  10.3390/ijerph14030301

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Marcelino Rivera
    • 1
  • Amy Krambeck
    • 1
  • James Lingeman
    • 1
  1. 1.Indiana University School of MedicineIndianapolisUSA

Personalised recommendations